Why hidradenitis suppurativa?

Why hidradenitis suppurativa?

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disorder that affects skin areas rich in apocrine glands. HS starts at early adolescence and it is affecting almost 1% of the general population. HS is characterized by exacerbations of heavy inflammation associated with extreme pain and limb and social disability. The Executive Board of the Hellenic Institute for the Study of Sepsis decided to support research activity in HS when data generated from the Out-Patients Department of Immunology of Infections of ATTIKON University Hospital showed that circulating white blood cells of patients with HS share common functional characteristics with sepsis patients thus making HS a study prototype of systemic inflammation.

Interventional Studies supported by the HISS

A double-blind, randomised, placebo-controlled clinical trial of the safety and efficacy of anakinra in patients with hidradenitis suppurativa study code HIDRA03, IS 92/11 permission by the National Organization for Medicines, 100/11 permission by the National Ethics Committee, EudraCT number 2011-005145-12, www.clinicaltrials.gov NCT: 01558375, phase 2 interventional study in two sites (enrolled patients 19)

An open label Phase II trial in patients with moderate to severe hidradenitis suppurativa to evaluate the safety of IFX-1 study code IFX-1-P2.3, IS 90/16 permission by the National Organization for Medicines, 92/16 permission by the National Ethics Committee, EudraCT number 2016-002988-33, www.clinicaltrials.gov NCT: 01558375, phase 2 interventional study in one site (enrolled patients 12)